Opinion on R&D in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: stopping Xenical from slimming down

Published By Datamonitor
10 Oct 2001
CommentWire
CommentWire

Roche: hoping for a better 2002

Much of the fall was due to the troubled vitamin and fine chemicals division, which Roche may well sell this year. However, the pharmaceutical division also had problems. Things may be better 2002, within the cardiovascular sphere at least. If weight loss drug Xenical is approved in type 2 diabetics, the market potential will be considerable.

Published By Datamonitor
01 Mar 2002
CommentWire
CommentWire

Roche: HIV announcement to dispel pipeline fears

Published By Datamonitor
21 Aug 2001
CommentWire
CommentWire

Roche/Schering-Plough: interferon therapy shows potential

According to French research, certain types of B cell lymphoma respond to the hepatitis C immunotherapy, interferon alfa. While this isn't the first time HCV has been linked with lymphoma, the results should still persuade makers of interferon alfa drugs, such as Roche and Schering-Plough to investigate usage in this indication.

Published By Datamonitor
15 Jul 2002
CommentWire
CommentWire

Roche/Genentech: Herceptin poised for an expanded role

Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.

Published By Datamonitor
14 Apr 2003
CommentWire
CommentWire

Roche/DeCODE: a long-term challenge for obesity and anxiety

Published By Datamonitor
14 Sep 2001
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: August 19 - 23, 2002

Last week's licensing news featured three of the world's biggest pharmaceutical companies: first GlaxoSmithKline joined Pfizer in an alliance with Argonaut, then Pharmacia joined forces with BattellePharma. Johns Hopkins University also had a busy week beating out deals with Crucell and Correlogic Systems. Finally Amgen and Praecis agreed to terminate their failed relationship.

Published By Datamonitor
23 Aug 2002
ResearchWire
ResearchWire

Personal care: convenience is second most important innovation driver, behind beauty

Published By Datamonitor
31 Jul 2001
ResearchWire
ResearchWire

Personal care products: natural ingredients are driving innovation

Published By Datamonitor
19 Jul 2001
CommentWire
CommentWire

Oxford GlycoSciences: Vevesca paves the way

Published By Datamonitor
26 Sep 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.